DOP2006000051A - Inhibidores de vegf-r2 y métodos - Google Patents

Inhibidores de vegf-r2 y métodos

Info

Publication number
DOP2006000051A
DOP2006000051A DO2006000051A DO2006000051A DOP2006000051A DO P2006000051 A DOP2006000051 A DO P2006000051A DO 2006000051 A DO2006000051 A DO 2006000051A DO 2006000051 A DO2006000051 A DO 2006000051A DO P2006000051 A DOP2006000051 A DO P2006000051A
Authority
DO
Dominican Republic
Prior art keywords
vegf
inhibitors
methods
compounds
formula
Prior art date
Application number
DO2006000051A
Other languages
English (en)
Inventor
David Anthony Barda
Timothy Paul Burkholder
Joshua Ryan Clayton
Yan Hao
Perry Clark Heath
James Robert Henry
John Monte Knobeloch
David Mendel
Johnathan Alexander Mclean
David Michael Remick
Mark Edward Rempala
Zhao-Qing Wang
Yvonne Yee Mai Yip
Boyu Zhong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2006000051A publication Critical patent/DOP2006000051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invencion provee compuestos que son inhibidores de VEGF-R2 de formula: asi como metodos usando tales compuestos.
DO2006000051A 2005-02-24 2006-02-22 Inhibidores de vegf-r2 y métodos DOP2006000051A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24

Publications (1)

Publication Number Publication Date
DOP2006000051A true DOP2006000051A (es) 2006-08-31

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000051A DOP2006000051A (es) 2005-02-24 2006-02-22 Inhibidores de vegf-r2 y métodos

Country Status (34)

Country Link
US (1) US7666879B2 (es)
EP (1) EP1904494B1 (es)
JP (1) JP5055136B2 (es)
KR (1) KR100904938B1 (es)
CN (1) CN101128461B (es)
AR (1) AR056186A1 (es)
AT (1) ATE490254T1 (es)
AU (1) AU2006216710B2 (es)
BR (1) BRPI0609047A2 (es)
CA (1) CA2599124C (es)
CR (1) CR9331A (es)
CY (1) CY1111154T1 (es)
DE (1) DE602006018615D1 (es)
DK (1) DK1904494T3 (es)
DO (1) DOP2006000051A (es)
EA (1) EA011691B1 (es)
ES (1) ES2354716T3 (es)
HK (1) HK1118284A1 (es)
HR (1) HRP20100677T1 (es)
IL (1) IL184717A (es)
MA (1) MA29433B1 (es)
MX (1) MX2007010326A (es)
NO (1) NO20074666L (es)
NZ (2) NZ584753A (es)
PE (1) PE20061098A1 (es)
PL (1) PL1904494T3 (es)
PT (1) PT1904494E (es)
RS (1) RS51590B (es)
SI (1) SI1904494T1 (es)
TN (1) TNSN07323A1 (es)
TW (1) TW200640924A (es)
UA (1) UA91535C2 (es)
WO (1) WO2006091671A1 (es)
ZA (1) ZA200707136B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
AU2007337895C1 (en) 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2008112164A2 (en) 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
KR20100076022A (ko) 2007-10-17 2010-07-05 노파르티스 아게 Ａｌｋ 억제제로서 유용한 이미다조 [１,２-ａ] 피리딘 유도체
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
AR090566A1 (es) * 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
KR102092988B1 (ko) 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
KR101735975B1 (ko) * 2012-11-29 2017-05-15 에프. 호프만-라 로슈 아게 이미다조피리딘 유도체
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
WO2015095128A1 (en) 2013-12-16 2015-06-25 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
CN107074778B (zh) * 2014-06-03 2019-12-13 代表亚利桑那大学的亚利桑那校董会 苯并咪唑类似物和相关方法
KR102485100B1 (ko) 2014-07-17 2023-01-04 선샤인 레이크 파르마 컴퍼니 리미티드 치환된 우레아 유도체 및 이의 약제학적 용도
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
AU2017232610B2 (en) * 2016-03-16 2021-07-22 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
EP3917932A4 (en) 2019-01-30 2022-09-28 Avista Pharma Solutions, Inc. CHEMICAL COMPOUNDS
CA3128346A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
EP3904355A4 (en) * 2019-02-18 2022-03-16 Shenzhen TargetRx, Inc. SUBSTITUTED CONDENSED AROMATIC RING DERIVATIVES, COMPOSITION AND THEIR USE
JP2022542645A (ja) * 2019-06-25 2022-10-06 シノプシー セラピューティクス 眼障害の治療のための化合物
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
DE60219793T2 (de) 2001-07-11 2008-01-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
ATE381332T1 (de) 2002-05-02 2008-01-15 Merck & Co Inc Tyrosinkinase-hemmer
AU2003299651A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
WO2005016928A1 (ja) 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体

Also Published As

Publication number Publication date
EA200701802A1 (ru) 2008-02-28
NZ584753A (en) 2011-06-30
DE602006018615D1 (de) 2011-01-13
ES2354716T3 (es) 2011-03-17
PL1904494T3 (pl) 2011-04-29
CN101128461A (zh) 2008-02-20
CN101128461B (zh) 2010-12-22
HK1118284A1 (en) 2009-02-06
KR20070099029A (ko) 2007-10-08
NO20074666L (no) 2007-11-09
JP5055136B2 (ja) 2012-10-24
RS51590B (en) 2011-08-31
NZ560402A (en) 2010-06-25
KR100904938B1 (ko) 2009-06-29
BRPI0609047A2 (pt) 2010-11-16
US7666879B2 (en) 2010-02-23
EA011691B1 (ru) 2009-04-28
SI1904494T1 (sl) 2011-02-28
CY1111154T1 (el) 2015-06-11
IL184717A (en) 2011-11-30
AU2006216710B2 (en) 2011-08-11
ATE490254T1 (de) 2010-12-15
MA29433B1 (fr) 2008-05-02
CR9331A (es) 2008-03-31
DK1904494T3 (da) 2011-02-21
AU2006216710A1 (en) 2006-08-31
HRP20100677T1 (hr) 2011-01-31
PE20061098A1 (es) 2006-10-20
US20090227622A1 (en) 2009-09-10
EP1904494B1 (en) 2010-12-01
JP2008531574A (ja) 2008-08-14
CA2599124A1 (en) 2006-08-31
EP1904494A1 (en) 2008-04-02
AR056186A1 (es) 2007-09-26
PT1904494E (pt) 2010-12-23
IL184717A0 (en) 2007-12-03
ZA200707136B (en) 2008-11-26
CA2599124C (en) 2013-08-06
MX2007010326A (es) 2007-10-16
UA91535C2 (en) 2010-08-10
TNSN07323A1 (en) 2008-12-31
WO2006091671A1 (en) 2006-08-31
TW200640924A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
DOP2006000051A (es) Inhibidores de vegf-r2 y métodos
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
MA32938B1 (fr) Composes organiques
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CR11861A (es) Compuestos organicos
IN2012DN03883A (es)
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2010007952A (es) Arilpirrolinas insecticidas.
CR20130045A (es) Compuestos terapéuticos
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
ATE400567T1 (de) Kinaseinhibitoren
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MY187449A (en) New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
DOP2005000010A (es) Inhibidores de quinasa
UY31688A1 (es) Plaguicidas
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
CR20140135A (es) Nuevos derivados de aril-quinolina
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION